DK1368054T3 - Anvendelse af neurale trådproteiner til behandling af tumorer - Google Patents

Anvendelse af neurale trådproteiner til behandling af tumorer

Info

Publication number
DK1368054T3
DK1368054T3 DK02733095T DK02733095T DK1368054T3 DK 1368054 T3 DK1368054 T3 DK 1368054T3 DK 02733095 T DK02733095 T DK 02733095T DK 02733095 T DK02733095 T DK 02733095T DK 1368054 T3 DK1368054 T3 DK 1368054T3
Authority
DK
Denmark
Prior art keywords
proteins
tumors
treatment
neural
wire
Prior art date
Application number
DK02733095T
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Pharmaceutical Corp filed Critical Nymox Pharmaceutical Corp
Application granted granted Critical
Publication of DK1368054T3 publication Critical patent/DK1368054T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
DK02733095T 2001-03-08 2002-03-08 Anvendelse af neurale trådproteiner til behandling af tumorer DK1368054T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27395701P 2001-03-08 2001-03-08
PCT/IB2002/001959 WO2002074323A2 (en) 2001-03-08 2002-03-08 Using neural thread proteins to treat tumors and other hyperproliferative disorders

Publications (1)

Publication Number Publication Date
DK1368054T3 true DK1368054T3 (da) 2008-02-04

Family

ID=23046145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02733095T DK1368054T3 (da) 2001-03-08 2002-03-08 Anvendelse af neurale trådproteiner til behandling af tumorer

Country Status (15)

Country Link
US (1) US20030054990A1 (da)
EP (2) EP1368054B1 (da)
JP (1) JP2004529908A (da)
KR (1) KR100632903B1 (da)
CN (1) CN1529613A (da)
AT (1) ATE374619T1 (da)
AU (1) AU2002304314B2 (da)
BR (1) BR0207638A (da)
CA (1) CA2439757A1 (da)
CY (1) CY1109650T1 (da)
DE (1) DE60222745T2 (da)
DK (1) DK1368054T3 (da)
ES (1) ES2295347T3 (da)
PT (1) PT1368054E (da)
WO (1) WO2002074323A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446480A1 (en) * 2001-05-04 2002-11-14 Nymox Corporation Method of preventing cell death using antibodies to neural thread proteins
BR0209630A (pt) * 2001-05-16 2004-03-30 Nymox Corp Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais
EP1541166B1 (en) * 2001-05-16 2007-12-19 Nymox Corporation Preventing cell death using segments of neural thread proteins
BR0209990A (pt) * 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
US7544771B2 (en) * 2005-02-23 2009-06-09 Nymox Corporation Protein and its use in diagnosing Alzheimer's disease
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
US8948878B2 (en) 2010-06-15 2015-02-03 Old Dominion University Research Foundation Method and device for treatment of conditions aggravated by amyloid fibrils
US9642687B2 (en) 2010-06-15 2017-05-09 The Procter & Gamble Company Methods for whitening teeth
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
CN108341854B (zh) * 2018-02-09 2020-02-18 中国医科大学 一种肿瘤靶向的新型多肽及其用途
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL93018C (da) * 1957-10-22
JPS5936174A (ja) * 1982-08-23 1984-02-28 Ricoh Co Ltd インクジエツト記録用水性インク
JPS59106989A (ja) * 1982-12-10 1984-06-20 Ricoh Co Ltd インクジエツト記録法
US4588998A (en) * 1983-07-27 1986-05-13 Ricoh Company, Ltd. Ink jet head having curved ink
US4994110A (en) * 1986-08-27 1991-02-19 Hewlett-Packard Company Dyes containing lithium for ink-jet printing inks
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US4874779A (en) * 1988-06-29 1989-10-17 Bristol-Myers Company Mitomycin phosphate derivatives
ES2094733T3 (es) * 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
US5462592A (en) * 1992-06-09 1995-10-31 Ricoh Company, Ltd. Aqueous ink composition
JP3176444B2 (ja) * 1992-10-01 2001-06-18 株式会社リコー 水性インク及びこれを用いた記録方法
JP3247784B2 (ja) * 1993-12-22 2002-01-21 株式会社リコー 水性インク及びこれを用いた記録方法
JP2888166B2 (ja) * 1995-04-04 1999-05-10 富士ゼロックス株式会社 インクジェット記録用インクおよびインクジェット記録方法
JP3620097B2 (ja) * 1995-04-28 2005-02-16 株式会社リコー 水性インク
JP3350839B2 (ja) * 1995-05-30 2002-11-25 株式会社リコー インクジェット記録用イエローインク及び画像記録方法
US5637138A (en) * 1995-06-06 1997-06-10 Brother Kogyo Kabushiki Kaisha Ink composition, process for its preparation, and ink-jet recording process
JP3475249B2 (ja) * 1996-07-25 2003-12-08 株式会社リコー 記録液及びそれを用いた記録方法
US5879439A (en) * 1996-08-01 1999-03-09 Ricoh Company, Ltd. Recording ink composition and recording method using the same
US6620922B1 (en) * 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP3583257B2 (ja) * 1997-03-17 2004-11-04 株式会社リコー 画像記録法及び画像記録装置並びに画像記録促進液
US6120589A (en) * 1998-02-20 2000-09-19 Ricoh Company, Ltd. Set of color ink compositions for ink-jet printing and method of forming color images using the color ink set
US6273985B1 (en) * 1998-06-26 2001-08-14 Xerox Corporation Bonding process
US6613136B1 (en) * 1999-09-17 2003-09-02 Ricoh Company, Ltd. Recording ink composition and ink-jet printing method using the same
CN1300779A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300778A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白15和编码这种多肽的多核苷酸
US6730155B2 (en) * 2000-06-30 2004-05-04 Ricoh Company, Ltd. Aqueous ink composition
JP3874336B2 (ja) * 2000-12-05 2007-01-31 株式会社リコー 記録液、これを用いたインクジェット記録方法及び記録用機器
US6730149B2 (en) * 2001-01-22 2004-05-04 Ricoh Company Limited Ink composition and inkjet recording method and apparatus using the ink composition
JP2002285047A (ja) * 2001-03-23 2002-10-03 Ricoh Co Ltd 水性記録液、該液を用いた記録方法および機器
BR0209990A (pt) * 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60218179T2 (de) * 2001-07-19 2007-11-22 Nymox Corp., Saint-Laurent Peptide zur behandlung von tumoren und anderen bedingungen, die die entfernung oder zerstörung von zellen erfordern

Also Published As

Publication number Publication date
CY1109650T1 (el) 2014-08-13
ES2295347T3 (es) 2008-04-16
DE60222745D1 (de) 2007-11-15
CA2439757A1 (en) 2002-09-26
US20030054990A1 (en) 2003-03-20
EP1368054A2 (en) 2003-12-10
AU2002304314B2 (en) 2007-09-06
KR100632903B1 (ko) 2006-10-13
EP1857115A2 (en) 2007-11-21
EP1857115A3 (en) 2008-08-06
DE60222745T2 (de) 2008-07-10
KR20040000403A (ko) 2004-01-03
JP2004529908A (ja) 2004-09-30
PT1368054E (pt) 2008-01-10
BR0207638A (pt) 2004-07-27
WO2002074323A3 (en) 2003-10-02
CN1529613A (zh) 2004-09-15
EP1368054B1 (en) 2007-10-03
ATE374619T1 (de) 2007-10-15
WO2002074323A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
CY1108009T1 (el) Αποτελεσματικα πεπτιδια στη θεραπεια ογκων ή αλλων ασθενειων που απαιτουν την εξαιρεση ή καταστροφη κυτταρων
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
NO20013493L (no) Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden